----item----
version: 1
id: {2091CF2F-1413-4D21-A687-28A44E8C8F2F}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/1995/07/31/Baxter stemcell separator enters Japanese trials
parent: {66DED1B6-66CF-446C-8FC9-AC5734A4B3CF}
name: Baxter stemcell separator enters Japanese trials
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: 7f5fe3de-00fe-4470-8cc7-644b5676c2c1

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 420

<p>Clinical trials with Baxter's Isolex 300 magnetic cell separator system began in Japan this month. Baxter says that Isolex, which has been granted orphan device status in Japan, is leading the field in the race to gain commercial registration of a stem-cell separator system in Japan. The exclusive status as an orphan device provides for streamlined premarketing review and government support of clinical trials.</p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 49

Baxter stem-cell separator enters Japanese trials
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1299

<p>Clinical trials with Baxter's Isolex 300 magnetic cell separator system began in Japan this month. Baxter says that Isolex, which has been granted orphan device status in Japan, is leading the field in the race to gain commercial registration of a stem-cell separator system in Japan. The exclusive status as an orphan device provides for streamlined premarketing review and government support of clinical trials.</p><p>Reinfusion of purified stem cells into cancer patients after high-dose chemotherapy has the potential to lower the risk of relapse and to reduce certain side-effects of stem-cell transplantation. The purification process with the Isolex system enables stem-cell-transplant material to be stored in small volumes, says Baxter.</p><p>The Isolex system comprises the basic cell-separation device; a disposable set of tubing and chamber; and a reagent kit incorporating Dynal's (Norway) immunomagnetic Dynabeads. Isolex was the first stem-cell separator system to receive the CE marking earlier this year (see Clinica No 638, p 19). Baxter plans to file an application with the FDA to begin US trials "late this year".</p><p>* An estimated 30,000 experimental high-dose chemotherapy treatments requiring blood-cell or marrow transplantation were performed worldwide last year.</p>
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 155

{6813DF9C-1DA9-44AE-9B9D-FB83827E8521}|{B2967A9C-ABDA-4628-A672-9EDDCD142AEA}|{2E0CEEF8-031D-43E8-B6AA-07D1397D9E4F}|{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 48

Baxter stemcell separator enters Japanese trials
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

19950731T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

19950731T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

19950731T000000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT053733
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 49

Baxter stem-cell separator enters Japanese trials
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

255542
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T184610Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

7f5fe3de-00fe-4470-8cc7-644b5676c2c1
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160622T184610Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
